Comparison of Three Complementary Analytical Techniques for the Evaluation of the Biosimilar Comparability of a Monoclonal Antibody and an Fc-Fusion Protein.
adalimumab
capillary gel electrophoresis
etanercept
reversed-phase liquid chromatography
size-exclusion chromatography
Journal
Frontiers in chemistry
ISSN: 2296-2646
Titre abrégé: Front Chem
Pays: Switzerland
ID NLM: 101627988
Informations de publication
Date de publication:
2021
2021
Historique:
received:
23
09
2021
accepted:
28
10
2021
entrez:
23
12
2021
pubmed:
24
12
2021
medline:
24
12
2021
Statut:
epublish
Résumé
In this work, a monoclonal antibody, adalimumab, and an Fc-fusion protein, etanercept, were studied and compared to one of their biosimilars. Samples submitted to stress conditions (agitation and high temperature) were used for method development. The developed methods were also applied to samples reduced by beta-mercaptoethanol to evaluate their capability to distinguish the expected species. Capillary gel electrophoresis (CGE), reversed-phase liquid chromatography (RPLC), and size-exclusion chromatography (SEC) methods coupled with UV detection were used to analyze the biopharmaceuticals. Their complementarity was investigated. For further molecular weight determination, SEC-multi angle light scattering and RPLC-quadrupole time-of-flight were occasionally used. For adalimumab, a larger amount of fragments and aggregates was observed in the biosimilar compared with the reference product. For etanercept, more related species were found in the reference product. Those three separation techniques showed good complementarity. Indeed, RPLC enabled the separation of hydrophilic and hydrophobic degradation products. CGE provided good selectivity for several adalimumab fragments, and SEC was useful for the analysis of aggregates and certain fragments that cannot be separated by the other approaches. Moreover, those formulations were submitted to mild stress conditions (30°C, 300 rpm for 4 h) that mimic shipping conditions. No additional peak was found under these conditions for the two studied biopharmaceuticals.
Identifiants
pubmed: 34938718
doi: 10.3389/fchem.2021.782099
pii: 782099
pmc: PMC8686473
doi:
Types de publication
Journal Article
Langues
eng
Pagination
782099Informations de copyright
Copyright © 2021 Demelenne, Ben Yahia, Lempereur, Crommen, Servais, Fradi and Fillet.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
BioDrugs. 2004;18(2):121-39
pubmed: 15046527
Anal Bioanal Chem. 2016 Feb;408(5):1523-30
pubmed: 26715251
MAbs. 2019 Jan;11(1):129-144
pubmed: 30296198
J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Oct 1;1096:1-10
pubmed: 30121339
Pharmaceutics. 2020 Dec 31;13(1):
pubmed: 33396369
Mol Cell Proteomics. 2017 Jul;16(7):1173-1187
pubmed: 28539326
J Pharm Biomed Anal. 2010 Dec 15;53(5):1236-43
pubmed: 20719453
Nat Rev Drug Discov. 2012 Jun 29;11(7):527-40
pubmed: 22743980
MAbs. 2014;6(6):1474-85
pubmed: 25484062
J Pharm Biomed Anal. 2015 Sep 10;113:43-55
pubmed: 25800161
J Pharm Sci. 2020 Jan;109(1):169-190
pubmed: 31465737
Anal Chem. 2017 May 2;89(9):4793-4797
pubmed: 28383250
J Sep Sci. 2021 Jan;44(1):35-62
pubmed: 32914936
MAbs. 2015;7(5):805-11
pubmed: 26230301
Talanta. 2019 Jul 1;199:457-463
pubmed: 30952283
MAbs. 2017 Nov/Dec;9(8):1217-1230
pubmed: 28853987
Eur J Pharm Biopharm. 2016 Jan;98:26-46
pubmed: 26542454
Anal Chem. 2006 Sep 15;78(18):6583-94
pubmed: 16970337
MAbs. 2019 Jan;11(1):116-128
pubmed: 30296204
Front Chem. 2017 Jan 18;4:49
pubmed: 28149835
J Vis Exp. 2019 Jun 20;(148):
pubmed: 31282880
Clin Ther. 1999 Jan;21(1):75-87; discussion 1-2
pubmed: 10090426
Cytokine. 2018 Jan;101:56-63
pubmed: 27567553
Pediatrics. 2016 Aug;138(2):
pubmed: 27432853
MAbs. 2019 Jul;11(5):930-941
pubmed: 30913973
Anal Biochem. 1996 Sep 5;240(2):155-66
pubmed: 8811899